1. ALLA AKTIER
  2. NYHETER
  3. SEDANA MEDICAL

Sedana Medical

Nyheter Sedana Medical Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Sedana Medical publishes its Annual Report for 2025

REG

Sedana Medical AB’s (publ) Annual Report describes important events and financial information for 2025, as well as the progress the company has made on its strategic priorities during the year.

“2025 was a successful year for Sedana Medical. For the first time as a listed company, we achieved profitability in our core business outside the United States, demonstrating the strength of our transformed operating model and establishing a stable, cash generating foundation for continued growth. At the same time, we made significant progress in reducing the risks related to US approval, including successful pivotal trials, FDA authorization of the Early Access Program, and positive regulatory interactions.", says Johannes Doll, President and CEO of Sedana Medical.

The Annual Report is available at www.sedanamedical.com.

For additional information, please contact:

Johannes Doll, CEO, +46 (0)76 303 66 66
Johan Spetz, CFO, +46 (0)730 36 37 89
ir@sedanamedical.com

This information is information that Sedana Medical AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-04-14 18:00 CEST.

About Sedana Medical

Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient’s life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.

Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.

Sedana Medical was founded in 2005, is listed on Nasdaq Stockholm (SEDANA) and headquartered in Stockholm, Sweden.

Attachments

Sedana Medical Annual Report 2025
sedanamedicalab-2025-12-31-1-sv

Datum 2026-04-14, kl 18:00
Källa MFN
Bifogade filer
Sedana Medical Annual Report 2025
sedanamedicalab-2025-12-31-1-sv